You are here: Industry Insights > SII

News List

AstraZeneca COVID-19 Vaccine Authorized for Emergency Use by WHO americanpharmaceuticalreview
February 19, 2021
AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals 18 years of age and older, including those over 65.
South Africa asks SII to take back one million doses of COVID-19 vaccine: Reports expresspharma
February 18, 2021
South Africa’s health minister had informed last week that the government could sell AstraZeneca’s vaccine.
India orders 14.5 mn more COVID-19 vaccine doses from SII and Bharat Biotech expresspharma
February 10, 2021
India has ordered 10 million more doses of the AstraZeneca COVID-19 vaccine from the (SII) and 4.5 million more of a homegrown one from Bharat Biotech, company representatives told Reuters.
Verity Pharma and India’s SII apply to distribute AstraZeneca vaccine in Canada expresspharma
February 03, 2021
Verity Pharmaceuticals and Serum Institute of India (SII) have applied to distribute SII’s licensed version of AstraZeneca’s COVID-19 vaccine in Canada, potentially easing shortages as European manufacturing sites struggle to meet global demand.
Serum Institute of India plans clinical trials of second Covid-19 vaccine pharmaceutical-technology
February 02, 2021
Serum Institute of India (SII) has announced plans to conduct clinical trials of another Covid-19 vaccine in the country, with hopes to launch it in June.
SII, Bharat Biotech welcome enhanced focus on health, immunisation in budget expresspharma
February 02, 2021
Government has increased allocation for the healthcare sector and alloted Rs 35,000 crore towards COVID-19 vaccination in 2021-22 fiscal.
Serum Institute of India seeks permission for local trials of Novavax vaccine expresspharma
February 01, 2021
Serum Institute of India (SII) has applied to the DCGI to conduct a small domestic trial of Novavax’s COVID-19 vaccine, which was found to be 89.3 per cent effective in a UK trial.
Local court rejects Cutis-Biotech’s trademark-violation lawsuit against SII over ‘Covishield’ expresspharma
February 01, 2021
SII had told the court that the two companies operate in different product categories and there is no scope for confusion over the trademark.
Five perish in fire at SII Pune facility, Covishield production unaffected expresspharma
January 22, 2021
No loss of Covishield production due to multiple production buildings that was kept in reserve to deal with such contingencies, informs Adar Poonawalla.
Serum Institute issues factsheet for Covishield expresspharma
January 20, 2021
Serum Institute of India (SII) has issued a factsheet of Covishield which includes details of the ingredients used in the COVID-19 vaccine.

Previous page 1 2 3 4 5 6 Next page